In the specialized field of immunology and neuroscience research, the MOG35 55 peptide sequence remains a cornerstone for understanding complex biological pathways. As someone who has long observed the evolution of peptide research, I have found that the precision of these synthetic sequences is what allows for such significant advancements MOG 35-55 humanis a fragment of the human protein MOG (Myelin Oligodendrocyte Glycoprotein – UniProtKB – Q16653),a minor constituent of the myelin sheath.Read more in controlled laboratory environments.
Defining the MOG35 55 Peptide Sequence
The MOG (35-55) fragment is derived from the Myelin Oligodendrocyte Glycoprotein, a protein found in the central nervous system. The standard peptide sequence for the rodent version is widely recognized in literature as: H-Met-Glu-Val-Gly-Trp-Tyr-Arg-Ser-Pro-Phe-Ser-Arg-Val-Val-His-Leu-Tyr-Arg-Asn-Gly-Lys-OH.
When examining the MOG 35-55 human variant, the structure is similarly critical for researchers studying how the body interacts with these specific epitopes. The sequence is often represented as MEVGWYRPPFSRVVHLYRNGK. The variation between these se Myelin Oligodendrocyte Glycoprotein (MOG 35-55), 25 mg quences—specifically the residues Citrullinated human and murine MOG35–55 display distinct at position 42 and 46—is a frequent topic of discussion in peptide study groups, as even minor changes can influence how MOG (35-55) interacts within a biological model.
Research Applications and Observations
My interest in this peptide stems from its role as an immunodominant epitope. In many laboratory models, the administration of MOG (35-55) is utilized to induce experimental autoimmune encephalomyelitis (EAE) in a rodent model. This is a standard procedure for studying the mechanisms of CNS-related inflammation.
I have noted that the purity of the high-purity MOG (35-55) peptide is paramount. Researchers often look for products with >90% purity, validated by HPLC/MS, to ensure that the MOG (35-5 Unlike immunization with the shortMOG35–55 peptide, human (hu)-MOG1–125 induced EAE involves B-cell recognition of the native MOG protein; the resultant Read more 5) (TFA) salt or other formulations do not introduce variables that could skew the results of their MOG 35-55 induced experimental autoimmune encephalomyelitis studies.
Key Considerations for Researchers:
* Structural Integrity: The H-Met-Glu-Val-Gly-Trp-Tyr-Arg-Ser-Pro-Phe-Ser-Arg-Val-Val-His-Leu sequence must be handled with care to prevent degradation.
* Immunological Response: The primary intent of using MOG Protein 35-55 is often to trigger the production of anti-MOG anti Unlike immunization with the shortMOG35–55 peptide, human (hu)-MOG1–125 induced EAE involves B-cell recognition of the native MOG protein; the resultant Read more bodies, which are Myelin Oligodendrocyte Glycoprotein Peptide Fragment 35-55was used to induce the disease model in rats and mice, providing insights into potential epigenetic Read more essential for mapping the progression of demyelination.
* Advanced Conjugates: Recent studies, such as those involving the Myelin Oligodendrocyte Glycoprotein (MOG) 35-55 mannan conjugate, show how modifying the delivery of this peptide can influence T-cell tolerance. It is fascinating to see how OM-MOG reversed clinical symptoms in specific research settings.
Navigating the Complexity of MOG (35-55)
Whether you are looking at MOG35 or the br MOG Protein 35-55is used as an antigen/immunogen to induce anti-MOG antibodies to induce experimental diseases such as experimental autoimmune oader Myelin Oligodendrocyte Glycoprotein peptides, the focus is always on the specificity of the binding. I have often compared notes with others regarding the Rat/Mouse Myelin Oligodendrocyte Glycoprotein 35-55 aa peptide and its stability. The Myelin Oligodendrocyte Glycoprotein (MOG) peptide 35-55 is not merely a reagent; it is a tool that requires a deep understanding of protein-protein interactions.
When sourcing, many researchers look for specific peptide catalogs that provide detailed mass spectrometry data. Given that MOG (35-55) produces a relapsing-remitting neurological disease pattern in research models, the reliability of the MOG (35-55) source material is the most important factor for consistent, reproducible data.
It is important to remember that these materials are strictly for research purposes. The study of MOG (35-55) is an ongoing journey into the complexities of the immune system, and as our techniques evolve, so too does our understanding of how this 55 peptide fragment functions within the broader context of Myelin Oligodendrocyte Glycoprotein MOG (35-55) research. Always ensure your documentation is thorough and your sourcing is reputable to maintain the highest standards of scientific integrity.